NPHS2 Conjugated Antibody

Catalog No: #C37775

Package Size: #C37775-AF350 100ul #C37775-AF405 100ul #C37775-AF488 100ul #C37775-AF555 100ul #C37775-AF594 100ul #C37775-AF647 100ul #C37775-AF680 100ul #C37775-AF750 100ul #C37775-Biotin 100ul

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	NPHS2 Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Species Reactivity	Hu Ms
Specificity	The antibody detects endogenous levels of total NPHS2 protein.
Immunogen Description	Synthetic peptide corresponding to residues near the C terminal of human nephrosis 2, idiopathic, steroid-resistant
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	PDCN; SRN1
Accession No.	Swiss-Prot#:Q9NP85NCBI Gene ID:7827NCBI mRNA#:NCBI Protein#:NP_000262
Uniprot	Q9NP85
GeneID	7827;
Excitation Emission	AF350: 346nm/442nm AF405: 401nm/421nm AF488: 493nm/519nm AF555: 555nm/565nm AF594: 591nm/614nm AF647: 651nm/667nm AF680: 679nm/702nm AF750: 749nm/775nm
Calculated MW	42
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°Cin dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250

AF405 conjugated: most applications: 1: 50 - 1: 250

AF488 conjugated: most applications: 1: 50 - 1: 250

AF555 conjugated: most applications: 1: 50 - 1: 250

AF594 conjugated: most applications: 1: 50 - 1: 250

AF647 conjugated: most applications: 1: 50 - 1: 250

AF680 conjugated: most applications: 1: 50 - 1: 250

AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

Background

This gene encodes the glomerular protein podocin which plays a role in the regulation of glomerular permeability, and acts as a linker between the plasma membrane and the cytoskeleton. Defects in this gene are the cause of autosomal recessive steroid-resistant nephrotic syndrome (SRN). SRN is characterized by onset between three months and five years, resistance to steroid therapy and rapid progression to end-stage renal disease. An alternative splice variant has been described but its full length sequence has not been determined.

Note: This product is for in vitro research use only